Finance entity
Every one of those 1 sits in a single category, markets. China is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 6, the average consequence score sits above the same-window beat average of 5.6.
Last mentioned: Aug 25, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. China is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 6, the average consequence score sits above the same-window beat average of 5.6. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. Ben Bradford appears in 1 tracked Finance story from August 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ben Bradford. Shared-story counts are live from our verified record — not editorial picks.
Investors see a bifurcated biotech recovery: hot IPOs and $79 billion in China-discovered licensing deals mask shrinking seed-stage venture funding. MassBio's 2026 report highlights how venture capital is concentrating in later-stage, less risky assets.
Source: biopharmadive.com · BioPharma Dive
Ben Bradford is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
